Page 224 - Mployee Wellness Programs News Today

Dr. Akram Boutros said in a lawsuit filed Monday in Cuyahoga County court that Cleveland-based MetroHealth’s board of directors violated open meeting laws when it “secretly hired” counsel to investigate him and then terminated him without mandatory public notice. 

The funding round was led by Optum Ventures. Other investors include Adams Street Partners, Blue Shield of California and Humana. DispatchHealth will use the money to expand its capabilities in current markets, its CEO said.

We now see the next wave of potential cancer therapies on the horizon, propelled by significant advancements in immunology, as well as an increased understanding of tumor-driven mechanisms of immune evasion.

Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children’s Hospital, University of California San Francisco, England’s National Health Service and Qure.ai.

AstraZeneca is jumping into the chase for cell therapies that address solid tumors by acquiring Neogene Therapeutics. The startup’s technology can be used to discover and develop novel targets that may be able to broaden the scope of cell therapies for cancer.

Covid-19 has forced us to face inequities present in health outcomes head-on and to recognize the systemic nature of health inequality that goes beyond the limits of what the healthcare system alone can change. The Quintuple Aim is a new framework for addressing these health inequities and centering our innovation and improvement efforts on marginalized communities and populations.

Eisai has presented and published full data from the Phase 3 clinical trial for its Alzheimer’s disease drug lecanemab, with results showing a statistically significant slowing decline associated with the neurodegenerative disorder. While an accelerated approval decision is expected in early 2023, the latest trial data are key because they represent the confirmatory study that could support an application for full FDA approval.

Miruna Sasu, CEO of RWE company COTA, explained that studies have shown meaningful improvements in efficiency if RWE is used in drug development and that translates into real savings. However, will such efforts continue amidst the ongoing belt-tightening in a tough economy?

While many will remember the Covid-19 pandemic as a source of disruption, it is likely that it will also be viewed as a catalyst for the transformation of medical education that had been brewing for the past decade.

As the healthcare industry prepares for a possible recession, Ash Shehata of KPMG expects to see more use of technology, targeted investments and an impact on consumers' wallets.